Tempus AI (TEM) announced it has received 510(k) clearance from the FDA for its Tempus ECG-Low EF software, which uses AI to identify certain patients who may have a low left ventricular ejection fraction.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEM:
- Cathie Wood’s ARK Investment bought 16.2K shares of Tempus AI today
- Moderately bullish activity in tempus AI Inc Class A with shares up 3.71%
- Cathie Wood Makes Her Largest Trade of the Day in This AI Stock, 7/10/2025
- Cathie Wood’s ARK Investment bought 151K shares of Tempus AI today
- Personalis expands Tempus AI strategic collaboration